Radiomics and theranostics with molecular and metabolic probes in prostate cancer: toward a personalized approach
Introduction In the last decade, two new radionuclide-based therapies, 223Radichloride and
radioligand therapy (RLT) targeting prostate-specific membrane antigen (PSMA), have been …
radioligand therapy (RLT) targeting prostate-specific membrane antigen (PSMA), have been …
Leptomeningeal disease in melanoma: An update on the developments in pathophysiology and clinical care
Leptomeningeal disease (LMD) remains a major challenge in the clinical management of
metastatic melanoma patients. Outcomes for patient remain poor, and patients with LMD …
metastatic melanoma patients. Outcomes for patient remain poor, and patients with LMD …
[HTML][HTML] Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer
J Calais, SM Eulau, L Gardner, RJ Hauke… - Cancer treatment …, 2023 - Elsevier
Prostate cancer (PC) is the second most commonly diagnosed cancer in the United States.
Advanced PC evolves to metastatic castration-resistant PC (mCRPC). Theranostics …
Advanced PC evolves to metastatic castration-resistant PC (mCRPC). Theranostics …
[64Cu]Cu-FAP-NOX, a N-oxalyl modified cyclic peptide for FAP PET imaging with a flexible imaging time window
S Liu, J Zhong, Z Zhang, R Zhao, Q Yan… - European Journal of …, 2024 - Springer
Background The aim of the present study was to develop a novel 64Cu-labeled cyclic
peptide ([64Cu] Cu-FAP-NOX) that targets fibroblast activation protein (FAP) and may offer …
peptide ([64Cu] Cu-FAP-NOX) that targets fibroblast activation protein (FAP) and may offer …
Development of [64Cu]Cu-BPAMD for PET imaging of bone metastases
S Zolghadri, F Badipa, H Yousefnia… - Radiochimica Acta, 2024 - degruyter.com
In this study, preclinical evaluation and dosimetric estimation of [64Cu] Cu-BPAMD, as a
new bone-seeking agent for PET imaging, was studied.[64Cu] Cu-BPAMD was produced …
new bone-seeking agent for PET imaging, was studied.[64Cu] Cu-BPAMD was produced …
Syntéza fosfono-bis (fosfinátového) derivátu cyklámu
M Chrappa - 2023 - dspace.cuni.cz
Radiofarmaka obsahující izotopy mědi jsou potenciálně využitelné pro diagnostiku (metody
PET, SPECT) nebo léčbu nádorů. Radionuklidy mědi musí být do těla aplikované ve formě …
PET, SPECT) nebo léčbu nádorů. Radionuklidy mědi musí být do těla aplikované ve formě …